$160,000.00 in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter

Share on StockTwits

Brokerages expect that Ascendis Pharma A/S (NASDAQ:ASND) will announce $160,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Ascendis Pharma A/S’s earnings. The lowest sales estimate is $20,000.00 and the highest is $230,000.00. Ascendis Pharma A/S posted sales of $510,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 68.6%. The business is scheduled to report its next earnings results on Thursday, November 15th.

On average, analysts expect that Ascendis Pharma A/S will report full year sales of $1.02 million for the current fiscal year, with estimates ranging from $100,000.00 to $3.00 million. For the next financial year, analysts forecast that the firm will report sales of $52.22 million per share, with estimates ranging from $80,000.00 to $156.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Ascendis Pharma A/S.

Several equities analysts have weighed in on the company. BidaskClub cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 16th. Stifel Nicolaus assumed coverage on Ascendis Pharma A/S in a report on Tuesday, June 26th. They set a “buy” rating and a $85.00 price target for the company. Canaccord Genuity assumed coverage on Ascendis Pharma A/S in a report on Tuesday, August 7th. They set a “buy” rating and a $81.00 price target for the company. Wells Fargo & Co raised their price target on Ascendis Pharma A/S from $83.00 to $88.00 and gave the company an “outperform” rating in a report on Thursday, August 30th. Finally, JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $79.00 to $81.00 and gave the company an “overweight” rating in a report on Thursday, August 30th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Ascendis Pharma A/S currently has an average rating of “Buy” and an average price target of $77.25.

NASDAQ ASND opened at $65.14 on Friday. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -15.04 and a beta of 0.67. Ascendis Pharma A/S has a 1-year low of $26.99 and a 1-year high of $76.99.

Institutional investors have recently made changes to their positions in the company. Atria Investments LLC purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth approximately $212,000. Quantbot Technologies LP purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth approximately $215,000. Kovack Advisors Inc. purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth approximately $218,000. Jane Street Group LLC purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth approximately $250,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth approximately $255,000. Hedge funds and other institutional investors own 95.29% of the company’s stock.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply